Ingredient news
Oral PS Trial Links Supplementation to Better Vascular Markers in Type 2 Diabetes
By Nutranexa News |
A randomized clinical study reported stronger load-related leg blood-flow responses and lower aortic stiffness after four weeks of oral phosphatidylserine in adults with type 2 diabetes.
What the Study Tested
The Journal of Applied Physiology paper combined in vitro work, diabetic-mouse testing, and a randomized, double-blind, placebo-controlled human trial in people with type 2 diabetes.
In the clinical arm, participants received phosphatidylserine supplementation for four weeks at 900 mg per day, delivering about 280 mg per day of phosphatidylserine.
What Changed
According to the abstract, supplementation improved leg blood-flow responses to an oral glucose load and reduced load-dependent aortic pulse wave velocity, a marker related to arterial stiffness.
The authors also linked PS to lower vascular oxidative stress and to inhibition of ADAM17, a pathway they propose is relevant to endothelial insulin resistance.
Buyer Takeaway
For PS suppliers, the paper broadens the current evidence conversation beyond cognition into cardiometabolic and vascular-support research.
Ingredient teams should still keep the study context clear: the publication is an early translational signal, not a finished-product claim template.